Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline

Br J Haematol. 2024 Jul;205(1):71-87. doi: 10.1111/bjh.19414. Epub 2024 Apr 25.

Abstract

A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug-drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.

Keywords: anticoagulation; cancer; venous thromboembolism; venous thrombosis.

Publication types

  • Practice Guideline

MeSH terms

  • Adult
  • Anticoagulants* / therapeutic use
  • Hemorrhage / chemically induced
  • Hemorrhage / etiology
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • United Kingdom
  • Venous Thromboembolism / etiology
  • Venous Thrombosis* / etiology

Substances

  • Anticoagulants